Skip to main content
SpringerLink
Log in

Sodium Oligomannate: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

A Correction to this article was published on 24 February 2020

This article has been updated

Abstract

Sodium oligomannate (九期一®; GV-971) is a marine algae-derived oral oligosaccharide being developed by Shanghai Green Valley Pharmaceuticals for the treatment of Alzheimer’s disease (AD). Sodium oligomannate received its first approval in November 2019 in China for the treatment of mild to moderate AD to improve cognitive function. This article summarizes the milestones in the development of sodium oligomannate leading to this first approval for AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 24 February 2020

    The first sentence, which currently reads: “Sodium oligomannate is produced by depolymerizing propylene glycol alginate sodium sulfate followed by oxidation, leaving carboxyl group at the reduced end [11].”

References

  1. Dong Y, Li X, Cheng J, et al. Drug development for Alzheimer’s disease: microglia induced neuroinflammation as a target? Int J Mol Sci. 2019;20(3):558.

    Article  CAS  Google Scholar 

  2. Panza F, Lozupone M, Logroscino G, et al. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15(2):73–88.

    Article  Google Scholar 

  3. Seo DO, Boros BD, Holtzman DM. The microbiome: a target for Alzheimer disease? Cell Res. 2019;29(10):779–80.

    Article  Google Scholar 

  4. Wang X, Sun G, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 2019;29(10):787–803.

    Article  CAS  Google Scholar 

  5. Shanghai Green Valley Pharmaceuticals. Milestones of oligomannate (GV-971) development. 2019. https://www.greenvalleypharma.com. Accessed 28 Nov 2019.

  6. Shanghai Green Valley Pharmaceuticals. Green Valley announces NMPA approval of oligomannate for mild to moderate Alzheimer’s disease [media release]. 2019. https://www.prnewswire.com.

  7. Reuters. China gives conditional OK to its first self-developed Alzheimer’s drug [media release]. 2019. https://www.reuters.com.

  8. Shanghai Green Valley Pharmaceuticals Co., Ltd. Sodium oligomannate capsules: Chinese prescribing information. 2019. https://www.greenvalleypharma.com/En/Index/listView/catid/81.html. Accessed 15 Jan 2020.

  9. China approves Alzheimer’s drug [news article]. Science. 2019;366(6466):668.

  10. Shanghai Institute of Materia Medica. China focus: China’s new Alzheimer’s drug completes phase 3 clinical trial. 2018. http://english.simm.cas.cn/. Accessed 28 Nov 2019.

  11. Gao Y, Zhang L, Jiao W. Chapter Seven: Marine glycan-derived therapeutics in China. Prog Mol Biol Transl Sci. 2019;163:113–4.

    Article  Google Scholar 

  12. Jiang RW, Du XG, Zhang X, et al. Synthesis and bioassay of beta-(1,4)-D-mannans as potential agents against Alzheimer’s disease. Acta Pharmacol Sin. 2013;34(12):1585–91.

    Article  CAS  Google Scholar 

  13. Xiao S. A phase II clinical trial on GV-971 in patients with Alzheimer’s [abstract no. OC 3]. J Prev Alz Dis. 2014;1(3):214–96.

    Google Scholar 

  14. Shi-fu X. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer disease [abstract]. Chin J Pharmacol Toxicol. 2019;6(6):403.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Yahiya Y. Syed

Authors
  1. Yahiya Y. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yahiya Y. Syed.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Syed is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

Enhanced material for this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshare.11290541. This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

The original has been updated: Due to textual changes.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Syed, Y.Y. Sodium Oligomannate: First Approval. Drugs 80, 441–444 (2020). https://doi.org/10.1007/s40265-020-01268-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-020-01268-1

Search

Navigation